J Korean Ophthalmol Soc > Volume 54(10); 2013 > Article
Journal of the Korean Ophthalmological Society 2013;54(10):1534-1539.
DOI: https://doi.org/10.3341/jkos.2013.54.10.1534    Published online October 15, 2013.
Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated for Age-Related Macular Degeneration.
Jung Jin Lee, Young Ju Lew, Sung Won Cho, Jong Woo Kim
Myung-Gok Eye Research Institute, Department of Ophthalmology, Kim's Eye Hospital, Konyang University, Seoul, Korea. yjlew@kimeye.com
삼출성 나이관련황반변성 반대안의 새로운 신생혈관 발생 빈도
Myung-Gok Eye Research Institute, Department of Ophthalmology, Kim’s Eye Hospital, Konyang University, Seoul, Korea
To investigate the development of new choroidal neovascularization in fellow eyes of patients treated for unilateral exudative age-related macular degeneration (AMD). METHODS: Three hundred fourteen patients who were first diagnosed with unilateral exudative AMD and treated with intravitreal bevacizumab or ranibizumab were studied retrospectively. RESULTS: New exudative AMD developed in 7.0% of fellow eyes after 1 year, 10.8% after 2 years and 13.7% after more than 2 years. According to the subtype of exudative AMD, there were no significant differences between classic CNV, occult or minimally classic CNV, and PCV in the incidence of new exudative AMD. After 2 years, a higher conversion rate was found in the bevacizumab-treated group than the ranibizumab-treated group. CONCLUSIONS: The cumulative incidence of involvement in fellow eyes with exudative AMD was 13.7% over 2 years.
Key Words: Bevacizumab;Exudative age-related macular degeneration;Incidence;Ranibizumab

Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2022 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next